Study guide

7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

Key Takeaways Explain This Topic AI

Intramuscular (IM) epinephrine into the anterolateral mid-thigh (vastus lateralis) at a dose of 0.3 to 0.5 mg (0.01 mg/kg in pediatrics, max 0.3 mg) of the 1 mg/mL (1:1,000) solution is the undisputed first-line definitive therapy for anaphylaxis, repeated every 5 to 15 minutes PRN.

Pharmacokinetic evidence proves that IM injection into the vastus lateralis achieves peak plasma epinephrine concentrations (Cmax) within approximately 8 minutes, compared to 34 minutes for subcutaneous administration and slower, erratic absorption via the deltoid muscle.

For refractory anaphylactic shock unresponsive to repeated IM epinephrine and rapid crystalloid volume expansion (1–2 L balanced fluids), continuous IV epinephrine infusion (0.1–1 mcg/kg/min or 1–10 mcg/min) or push-dose epinephrine (10–20 mcg IV q2–5min) must be initiated immediately.

In patients taking chronic beta-adrenergic blockers who experience refractory anaphylactic shock, intravenous glucagon (1–5 mg slow IV over 5 minutes followed by 5–15 mcg/min infusion) bypasses blocked beta receptors to activate adenylyl cyclase directly, requiring lateral decubitus positioning due to severe vomiting.

Second-line adjunctive agents (H1-antihistamines, H2-antihistamines, and systemic corticosteroids) treat only cutaneous symptoms, have no effect on laryngeal edema or distributive shock, do not reliably prevent biphasic reactions, and must never delay epinephrine administration.

Last updated: October 2026

7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

Note

Independent BCEMP study resource provided by ExamFinch. Content covers Board of Pharmacy Specialties (BPS) Emergency Medicine Pharmacy examination topics.

Clinical Definition & NIAID/FAAN Diagnostic Criteria

Anaphylaxis is an acute, life-threatening, multi-system syndrome triggered by the sudden, systemic release of inflammatory mediators (histamine, tryptase, platelet-activating factor, leukotrienes C4/D4/E4, prostaglandin D2) from mast cells and basophils. While classically mediated by allergen-specific immunoglobulin E (IgE), non-IgE-mediated anaphylactoid reactions (e.g., radiocontrast media, vancomycin, opioids) present with clinically indistinguishable physiological collapses and require identical emergency management.

According to the National Institute of Allergy and Infectious Disease / Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria, anaphylaxis is highly likely when any one of three clinical scenarios is satisfied: NIAID/FAAN DIAGNOSTIC PHENOTYPES

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ CRITERION 1: ACUTE ONSET (Minutes to Hours) WITH SKIN / MUCOSAL SIGNS │
  • │ (Generalized hives, pruritus, flushing, swollen lips/tongue/uvula) PLUS: │
  • │ • Respiratory Compromise (Dyspnea, wheeze, stridor, hypoxemia, PEF drop) │
  • │ OR │
  • │ • Reduced Blood Pressure / End-Organ Dysfunction (Syncope, hypotonia) │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ CRITERION 2: TWO OR MORE RAPID SIGNS AFTER A LIKELY ALLERGEN │
  • │ 1. Skin/Mucosal Involvement (Hives, swollen lips, flushing) │
  • │ 2. Respiratory Compromise (Stridor, wheezing, cough, hypoxemia) │
  • │ 3. Reduced Blood Pressure or Associated Symptoms (Collapse, syncope) │
  • │ 4. Persistent Gastrointestinal Cramping / Vomiting / Diarrhea │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ CRITERION 3: REDUCED BLOOD PRESSURE AFTER A KNOWN ALLERGEN │
  • │ • Adults: Systolic BP <90 mmHg OR >30% decrease from baseline │
  • │ • Infants/Children: Low age-specific SBP OR >30% decrease from baseline │
  • └─────────────────────────────────────────────────────────────────────────────┘

Important

Up to 10% to 20% of severe, fatal anaphylactic episodes present with zero cutaneous manifestations . Patients presenting with rapid cardiovascular collapse or severe bronchospasm following parenteral medication or venom exposure must receive immediate epinephrine even in the complete absence of urticaria or angioedema.

First-Line Definitive Pharmacotherapy: Epinephrine

Epinephrine (adrenaline) is the undisputed first-line medication for anaphylaxis. There are no absolute contraindications to epinephrine administration in a life-threatening anaphylactic emergency.

Dosing, Formulation & Administration Route

Drug Concentration : 1 mg/mL (1:1,000 solution) formulation.

Route of Administration : INTRAMUSCULAR (IM) injection administered into the anterolateral mid-thigh (vastus lateralis) .

Adult Dosing : 0.3 to 0.5 mg IM (0.3 to 0.5 mL of 1 mg/mL solution).

Pediatric Dosing : 0.01 mg/kg IM (up to a single maximum dose of 0.3 mg ), or weight-tiered autoinjectors:

Labeled weight bands: 0.1 mg autoinjector for infants 7.5 to 15 kg; 0.15 mg for 15 to 30 kg; 0.3 mg for 30 kg and above.

The American Academy of Pediatrics suggests moving to the 0.3 mg device at about 25 kg.

Nasal epinephrine (neffy) is an FDA-approved needle-free alternative: 2 mg for patients 30 kg and above (2024) and 1 mg for children 15 to 30 kg (2025). It is useful for patients who will not carry or use a needle device.

Dosing Frequency : May be repeated every 5 to 15 minutes based on hemodynamic and airway response. Most patients responding to IM epinephrine require 1 to 2 doses.

Pharmacokinetics: Why the Vastus Lateralis is Mandatory

Landmark pharmacokinetic investigations led by Estelle Simons evaluated plasma epinephrine concentrations following different routes and anatomical injection sites: PEAK PLASMA EPINEPHRINE KINETICS (Cmax)

  • ┌───────────────────────────────────────────────────────────────────────────┐
  • │ Intramuscular Mid-Thigh (Vastus Lateralis): Peak Cmax in ~8 ± 2 minutes │
  • │ • Massive vascularity of vastus lateralis ensures rapid drug uptake │
  • │ • First-line standard of care across all international resuscitation guidelines│
  • ├───────────────────────────────────────────────────────────────────────────┤
  • │ Subcutaneous (SC) Injection: Peak Cmax in ~34 ± 14 minutes │
  • │ • Delayed, erratic absorption; local alpha-1 vasoconstriction impedes entry│
  • │ • Unacceptable therapeutic delay during acute vascular collapse │
  • ├───────────────────────────────────────────────────────────────────────────┤
  • │ Intramuscular Deltoid: Slower, erratic absorption compared to thigh │
  • │ • Lower local blood flow compared to vastus lateralis in shock states │
  • └───────────────────────────────────────────────────────────────────────────┘

During anaphylactic shock, cutaneous and subcutaneous blood flow is severely compromised due to peripheral shunting and microvascular collapse. Subcutaneous epinephrine injection triggers intense localized alpha-1 vasoconstriction, trapping the drug in the hypodermis and delaying systemic peak concentrations for over half an hour. Consequently, subcutaneous administration is obsolete and clinically contraindicated in anaphylaxis.

Receptor Pharmacodynamics

Epinephrine is an agonist across alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors, providing comprehensive physiological reversal of every organ system derangement:

Alpha-1 Adrenergic Stimulation : Reverses peripheral vasodilation, increases systemic vascular resistance, elevates diastolic blood pressure, and reduces post-capillary venular permeability, rapidly decreasing mucosal edema and relieving laryngeal obstruction.

Beta-1 Adrenergic Stimulation : Increases cardiac contractility (positive inotropy) and heart rate (positive chronotropy), restoring forward stroke volume and cardiac output.

Beta-2 Adrenergic Stimulation : Produces immediate bronchial smooth muscle relaxation (bronchodilation). Furthermore, beta-2 receptor activation on mast cell and basophil membranes stimulates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP). High cAMP levels directly inhibit further mast cell degranulation , terminating the release of histamine, leukotrienes, and cytokines at the source.

Refractory Anaphylaxis & Vascular Collapse Protocols

Refractory anaphylaxis is defined as persistent hypotension, upper airway obstruction, or severe bronchospasm despite 2 to 3 appropriately dosed IM epinephrine injections and initial IV fluid resuscitation.

Pathophysiology of Anaphylactic Shock

Anaphylactic shock is a distributive and hypovolemic crisis. Systemic inflammatory mediators trigger widespread arteriolar dilation and massive post-capillary venular permeability. Up to 35% of the total intravascular circulating blood volume can shift into the interstitial space within 10 minutes , resulting in profound hemoconcentration, decreased venous return, and empty cardiac chambers.

Aggressive Fluid Resuscitation

Adults : Rapid infusion of 1 to 2 liters of balanced crystalloids (e.g., Lactated Ringer's or Plasma-Lyte) administered via large-bore IV catheters under pressure bags.

Pediatrics : 20 mL/kg crystalloid boluses repeated up to 40 to 60 mL/kg in the first hour.

Intravenous Epinephrine Continuous Infusion

When hypotension persists despite IM epinephrine and fluid loading, intravenous epinephrine must be started without delay. Intravenous boluses of undiluted 1 mg/mL or 0.1 mg/mL epinephrine can cause lethal ventricular fibrillation, myocardial ischemia, and intracranial hemorrhage; infusions must be diluted and titratable.

Standard Infusion Concentration : 1 mg epinephrine (1 mL of 1 mg/mL) added to 250 mL of D5W or 0.9% normal saline (concentration = 4 mcg/mL ).

Weight-Based Dosing : 0.1 to 1.0 mcg/kg/minute IV infusion titrated to mean arterial pressure (MAP ≥65 mmHg) and airway improvement.

Non-Weight-Based Dosing : 1 to 10 mcg/minute IV infusion (starting at 1 to 2 mcg/min and titrating rapidly).

Push-Dose Epinephrine (Bridging Therapy)

Push-dose epinephrine provides immediate, temporary hemodynamic support while an infusion pump and bag are compounded:

Compounding Protocol : Take 1 mL of cardiac epinephrine 0.1 mg/mL (1:10,000) (which contains 100 mcg) and draw it into a syringe containing 9 mL of 0.9% normal saline. The resulting 10 mL solution has a concentration of 10 mcg/mL .

Dosing : Administer 10 to 20 mcg IV bolus (1 to 2 mL) every 2 to 5 minutes titrated to blood pressure.

Tip

If peripheral extravasation of an epinephrine infusion occurs, immediately infiltrate the affected tissue with phentolamine (5 to 10 mg diluted in 10 mL normal saline) via fine needle to block alpha-1 vasoconstriction and prevent ischemic tissue necrosis.

Beta-Blocker Associated Anaphylaxis & The Glucagon Protocol

Patients on chronic beta-adrenergic antagonist therapy (e.g., metoprolol, carvedilol, propranolol, atenolol) who experience anaphylaxis present a unique, high-mortality clinical emergency. BETA-BLOCKER OVERRIDE MECHANISM: GLUCAGON

  • ┌───────────────────────────────────────────────────────────────────────────┐
  • │ Epinephrine ──► Beta-1 / Beta-2 Receptors BLOCKED by Beta-Blockers │
  • │ (Unopposed alpha-1: Severe Bradycardia & Refractory Shock)│
  • ├───────────────────────────────────────────────────────────────────────────┤
  • │ Glucagon ─────► Specific Myocardial GLUCAGON RECEPTORS (Non-Adrenergic) │
  • │ (Directly stimulates Adenylyl Cyclase ──► ↑ cAMP) │
  • │ (Restores Heart Rate, Inotropy, and Bronchial Relaxation) │
  • └───────────────────────────────────────────────────────────────────────────┘
  • Pathophysiological Dilemma

Competitive beta-receptor blockade prevents epinephrine from stimulating myocardial beta-1 and bronchial/mast-cell beta-2 receptors. Furthermore, administering epinephrine in the presence of severe beta-blockade leaves alpha-1 receptors unopposed, triggering massive peripheral vasoconstriction that can induce severe reflex bradycardia, profound cardiogenic/distributive shock, and fatal cardiovascular collapse.

Glucagon Administration Protocol

Mechanism : Glucagon binds to independent, non-adrenergic G-protein-coupled glucagon receptors on the myocardium and airway smooth muscle. This bypasses adrenergic receptors entirely to activate adenylyl cyclase directly, increasing intracellular cAMP, augmenting calcium entry, and restoring heart rate, cardiac contractility, and bronchodilation.

Dosing Regimen :

Initial Bolus : 1 to 5 mg IV administered slowly over 5 minutes .

Maintenance Infusion : 5 to 15 mcg/minute continuous IV infusion titrated to clinical response.

Adverse Effects & Essential Precaution : Rapid administration of IV glucagon induces severe nausea and intractable vomiting in almost all conscious patients due to acute relaxation of the lower esophageal sphincter and gastric smooth muscle.

Aspiration Prevention : Patients receiving IV glucagon must be placed in the lateral decubitus position with active oral suction immediately available at the bedside. Pre-treatment or concurrent administration of IV ondansetron (4 to 8 mg) is recommended.

Second-Line Adjuncts & Clinical Misconceptions

Antihistamines and systemic corticosteroids are categorized as second-line adjunctive therapies . A major cause of preventable anaphylaxis fatalities is the inappropriate administration of antihistamines or steroids instead of or prior to epinephrine.

Medication Class Agent & Emergency Dosing Clinical Scope & Limitations Critical BCEMP Board Concept

H1-Antihistamine Diphenhydramine : 25 to 50 mg IV or PO (Pediatric: 1 mg/kg, max 50 mg) Relieves cutaneous itching, urticaria, and angioedema. Causes drowsiness and anticholinergic dry mouth. Does NOT relieve stridor, wheezing, or shock . Rapid IV push can worsen hypotension. Never delays epinephrine.

H2-Antihistamine Famotidine : 20 mg IV or PO (Pediatric: 0.5 mg/kg, max 20 mg) Blocks vascular and cardiac H2 receptors. Provides synergistic cutaneous relief when combined with H1 blockers. Does not treat airway edema or shock. Minor adjunctive role only.

Systemic Corticosteroids Methylprednisolone : 1 to 2 mg/kg IV (max 125 mg); Prednisone : 1 mg/kg PO (max 50–60 mg) Alters nuclear transcription to suppress secondary cytokine production. Zero effect in acute resuscitation due to 4–6 hour genomic lag time . Recent meta-analyses confirm steroids do NOT prevent biphasic anaphylaxis .

Warning

Antihistamines and corticosteroids have zero impact on laryngeal edema, bronchospasm, or cardiovascular collapse . Under no circumstances should an emergency team prepare, administer, or wait for second-line medications before injecting intramuscular epinephrine into the vastus lateralis.

  • Biphasic Anaphylaxis & ED Disposition Protocols
  • Biphasic Reactions

Biphasic anaphylaxis is defined as the recurrence of systemic anaphylactic symptoms following complete clinical resolution of the initial event without re-exposure to the culprit allergen.

Incidence : About 5% of anaphylaxis cases in pooled data (reported range roughly 1% to 20%).

Timeline : Typically manifests within 4 to 12 hours after resolution of the primary episode, though documented cases have occurred up to 72 hours later.

Independent Risk Factors :

Delayed initial epinephrine administration (>30 to 60 minutes from symptom onset).

Severe initial clinical presentation (hemodynamic shock, wide pulse pressure, respiratory failure).

Requirement for more than one dose of epinephrine during initial resuscitation.

Prior history of biphasic anaphylaxis.

Observation Duration & Discharge Bundle

Observation Guidelines : Patients with moderate-to-severe anaphylaxis or those requiring multiple epinephrine doses must be observed in the emergency department for a minimum of 4 to 8 hours from symptom resolution. Patients who experienced refractory shock requiring IV infusions should be admitted to an ICU or step-down unit for 24 hours of observation.

Discharge Prescription : Patients must be discharged with a prescription for two (2) epinephrine autoinjectors (e.g., 0.3 mg or 0.15 mg), a personalized written anaphylaxis action plan, hands-on demonstration of device technique, education on trigger avoidance, and a referral to an allergy and immunology specialist.